Identification and HLA-tetramer-validation of human CD4+and CD8+ T cell responses against HCMV proteins IE1 and IE2

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Braendstrup, Peter ^a,b   Mortensen, Bo Kok ^a,b   Justesen, Sune ^a   Østerby, Thomas ^a   Rasmussen, Michael ^a   Hansen, Andreas Martin ^a   Christiansen, Claus Bohn ^b   Hansen, Morten Bagge ^b   Nielsen, Morten ^c,d   Vindeløv, Lars ^b   Buus, Søren ^a   Stryhn, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; IMMEDIATE EARLY PROTEIN 2; TETRAMER; UNCLASSIFIED DRUG; EPITOPE; IE1 PROTEIN, CYTOMEGALOVIRUS; IE2 PROTEIN, CYTOMEGALOVIRUS; TRANSACTIVATOR PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; EX VIVO STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BINDING; PROTEIN EXPRESSION; VALIDATION STUDY; DENDRITIC CELL; IMMUNOLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOMEGALOVIRUS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMEDIATE-EARLY PROTEINS; TRANS-ACTIVATORS;

EID: 84899733929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094892     Document Type: Article

References (79)

1. Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20: 202-213.
2. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, et al. (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407-414. (Pubitemid 36077556)
3. Boeckh M, Nichols WG (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008. (Pubitemid 38326213)
4. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, et al. (1988) Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109: 777-782. (Pubitemid 19046044)
5. Emery VC (2001) Investigation of CMV disease in immunocompromised patients. J Clin Pathol 54: 84-88.
6. Walker CM, van Burik JA, De For TE, Weisdorf DJ (2007) Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 13: 1106-1115. (Pubitemid 47240751)
7. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK (2013) The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 26: 86-102.
8. Soroceanu L, Cobbs CS (2011) Is HCMV a tumor promoter? Virus Res 157: 193-203.
9. Khan Z, Yaiw KC, Wilhelmi V, Lam H, Rahbar A, et al. (2014) Human cytomegalovirus immediate early proteins promote degradation of connexin 43 and disrupt gap junction communication: implications for a role in gliomagenesis. Carcinogenesis 35: 145-154.
10. Soderberg-Naucler C, Rahbar A, Stragliotto G (2013) Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 369: 985-986.
11. Griffiths PD (2012) Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis 12: 790-798.
12. Khare MD, Sharland M (2001) Cytomegalovirus treatment options in immunocompromised patients. Expert Opin Pharmacother 2: 1247-1257. (Pubitemid 32750363)
13. Reusser P, Riddell SR, Meyers JD, Greenberg PD (1991) Cytotoxic Tlymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78: 1373-1380.
14. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, et al. (2006) Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108: 1406-1412. (Pubitemid 44232045)
15. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, et al. (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673-685. (Pubitemid 41248418)
16. Emery VC, Einsele H, Atabani S, Haque T (2010) Immunotherapy and vaccination after transplant: the present, the future. Infect Dis Clin North Am 24: 515-529.
17. Sellar RS, Peggs KS (2012) Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin Biol Ther 12: 1161-1172.
18. Fuji S, Kapp M, Grigoleit GU, Einsele H (2011) Adoptive immunotherapy with virus-specific T cells. Best Pract Res Clin Haematol 24: 413-419.
19. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, et al. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386. (Pubitemid 41126955)
20. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, et al. (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922. (Pubitemid 35332029)
21. Peggs KS, Verfuerth S, Pizzey A, Khan N, Moss P, et al. (2003) Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 9: 198-205.
22. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, et al. (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121: 5113-5123.
23. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, et al. (2011) Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirusspecific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51: 591-599.
24. Ebert S, Podlech J, Gillert-Marien D, Gergely KM, Buttner JK, et al. (2012) Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection. Med Microbiol Immunol 201: 527-539.
25. Thomsen AR, Johansen J, Marker O, Christensen JP (1996) Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virusinfected MHC class II-deficient mice and B cell-deficient mice. J Immunol 157: 3074-3080. (Pubitemid 126450067)
26. Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342. (Pubitemid 36433727)
27. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
28. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, et al. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
29. Bronke C, Jansen CA, Westerlaken GH, De Cuyper IM, Miedema F, et al. (2007) Shift of CMV-specific CD4+ T-cells to the highly differentiated CD45RO-CD27- phenotype parallels loss of proliferative capacity and precedes progression to HIV-related CMV end-organ disease. Clin Immunol 124: 190-199. (Pubitemid 47059042)
30. Rooney C, Leen A (2012) Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials. Mol Ther Nucleic Acids 1: e55.
31. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, et al. (2005) Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 174: 8210-8218. (Pubitemid 40806333)
32. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, et al. (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19: 4652-4660. (Pubitemid 32800747)
33. Sette A, Livingston B, McKinney D, Appella E, Fikes J, et al. (2001) The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29: 271-276. (Pubitemid 34093652)
34. Stinski MF, Meier JL (2007) Immediate-early viral gene regulation and function. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B et al., editors.Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press 2007.
35. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, et al. (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201: 1031-1036. (Pubitemid 40524670)
36. Marchini A, Liu H, Zhu H (2001) Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J Virol 75: 1870-1878. (Pubitemid 32110177)
37. Greaves RF, Mocarski ES (1998) Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J Virol 72: 366-379. (Pubitemid 28048848)
38. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, et al. (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25: 2823-2831. (Pubitemid 46420615)
39. Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, et al. (2005) Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 28: 63-72. (Pubitemid 40075939)
40. Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, et al. (2008) One-pot, mix-and-read peptide-MHC tetramers. PLoS One 3: e1678.
41. Braendstrup P, Justesen S, Osterbye T, Nielsen LL, Mallone R, et al. (2013) MHC class II tetramers made from isolated recombinant alpha and beta chains refolded with affinity-tagged peptides. PLoS One 8: e73648.
42. Erup Larsen M, Kloverpris H, Stryhn A, Koofhethile CK, Sims S, et al. (2011) HLArestrictor - a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 63: 43-55.
43. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S (2010) NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6: 9.
44. Harndahl M, Justesen S, Lamberth K, Roder G, Nielsen M, et al. (2009) Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J Biomol Screen 14: 173-180.
45. Justesen S, Harndahl M, Lamberth K, Nielsen LL, Buus S (2009) Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res 5: 2.
46. Harndahl M, Rasmussen M, Roder G, Buus S (2011) Real-time, highthroughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods 374: 5-12.
47. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, et al. (2001) Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 255: 27-40.
48. Schmidt AH, Baier D, Solloch UV, Stahr A, Cereb N, et al. (2009) Estimation of high-resolution HLA-A, -B, -C, -DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning. Hum Immunol 70: 895-902.
49. Nepom GT (2012) MHC class II tetramers. J Immunol 188: 2477-2482.
50. Sette A, Buus S, Colon S, Smith JA, Miles C, et al. (1987) Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 328: 395-399. (Pubitemid 17097771)
51. Harndahl M, Rasmussen M, Roder G, Dalgaard Pedersen I, Sorensen M, et al. (2012) Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 42: 1405-1416.
52. Khan N, Best D, Bruton R, Nayak L, Rickinson AB, et al. (2007) T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 178: 4455-4465. (Pubitemid 46492397)
53. Nastke MD, Herrgen L, Walter S, Wernet D, Rammensee HG, et al. (2005) Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci 62: 77-86. (Pubitemid 40933094)
54. Elkington R, Walker S, Crough T, Menzies M, Tellam J, et al. (2003) Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77: 5226-5240. (Pubitemid 36460937)
55. Gibson L, Dooley S, Trzmielina S, Somasundaran M, Fisher D, et al. (2007) Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants. J Infect Dis 195: 1789-1798. (Pubitemid 46870252)
56. Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, et al. (2007) CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med 5: 17.
57. Kirchner A, Hoffmeister B, Cherepnev GG, Fuhrmann S, Streitz M, et al. (2008) Dissection of the CMV specific T-cell response is required for optimized cardiac transplant monitoring. J Med Virol 80: 1604-1614.
58. Kern F, Surel IP, Faulhaber N, Frommel C, Schneider-Mergener J, et al. (1999) Target structures of the CD8 (+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 73: 8179-8184. (Pubitemid 29441679)
59. Khan N, Cobbold M, Keenan R, Moss PA (2002) Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 185: 1025-1034. (Pubitemid 34297759)
60. Frankenberg N, Pepperl-Klindworth S, Meyer RG, Plachter B (2002) Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295: 208-216. (Pubitemid 34921306)
61. Ameres S, Mautner J, Schlott F, Neuenhahn M, Busch DH, et al. (2013) Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion. PLoS Pathog 9: e1003383.
62. Alp NJ, Allport TD, Van Zanten J, Rodgers B, Sissons JG, et al. (1991) Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. J Virol 65: 4812-4820.
63. Davignon JL, Castanie P, Yorke JA, Gautier N, Clement D, et al. (1996) Antihuman cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol 70: 2162-2169. (Pubitemid 26087575)
64. Gautier N, Chavant E, Prieur E, Monsarrat B, Mazarguil H, et al. (1996) Characterization of an epitope of the human cytomegalovirus protein IE1 recognized by a CD4+ T cell clone. Eur J Immunol 26: 1110-1117. (Pubitemid 26158510)
65. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, et al. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19: 2237-2242. (Pubitemid 20024747)
66. Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO (2003) Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol 1: E65.
67. Stone JD, Demkowicz WE Jr, Stern LJ (2005) HLA-restricted epitope identification and detection of functional T cell responses by using MHCpeptide and costimulatory microarrays. Proc Natl Acad Sci U S A 102: 3744-3749. (Pubitemid 40354682)
68. Ge X, Gebe JA, Bollyky PL, James EA, Yang J, et al. (2010) Peptide-MHC cellular microarray with innovative data analysis system for simultaneously detecting multiple CD4 T-cell responses. PLoS One 5: e11355.
69. Hoff A, Bagu AC, Andre T, Roth G, Wiesmuller KH, et al. (2010) Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells. Cancer Immunol Immunother 59: 1379-1387.
70. Buus S, Rockberg J, Forsstrom B, Nilsson P, Uhlen M, et al. (2012) Highresolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays. Mol Cell Proteomics 11: 1790-1800.
71. Kotturi MF, Peters B, Buendia-Laysa F Jr, Sidney J, Oseroff C, et al. (2007) The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus. J Virol 81: 4928-4940. (Pubitemid 46744404)
72. Lundegaard C, Lund O, Nielsen M (2012) Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy? Expert Rev Vaccines 11: 43-54.
73. Zhang L, Udaka K, Mamitsuka H, Zhu S (2012) Toward more accurate panspecific MHC-peptide binding prediction: a review of current methods and tools. Brief Bioinform 13: 350-364.
74. Vollers SS, Stern LJ (2008) Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 123: 305-313. (Pubitemid 351171199)
75. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, et al. (2009) Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 126: 147-164.
76. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, et al. (2013) A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics 65: 357-370.
77. Rist M, Cooper L, Elkington R, Walker S, Fazou C, et al. (2005) Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur J Immunol 35: 996-1007. (Pubitemid 40425556)
78. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, et al. (2007) Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 9: 165-170. (Pubitemid 46669086)
79. Krishnan A, Wang Z, Srivastava T, Rawal R, Manchanda P, et al. (2008) A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. Immunol Lett 120: 108-116.